Lloyd Doggett
Price Movement Since Trade
How each stock has moved from the trade date to the most recent close.
Suspicious Timing Detected
5 flagsRep. Doggett bought $1,001 - $15,000 in $JNJ on March 4, 2025, two days before the Access to Pediatric Technologies Act of 2025 (HR1931) was introduced, a bill that could benefit medical device manufacturers.
Rep. Doggett bought $1,001 - $15,000 in $JNJ on March 4, 2025, six days before the American Innovation and R&D Competitiveness Act of 2025 (HR1990) was introduced, which aims to restore immediate expensing for R&D costs.
Rep. Doggett bought $1,001 - $15,000 in $JNJ on March 4, 2025, 23 days before the Providing Veterans Essential Medications Act (HR1970) was introduced, a bill that aims to shift the financial burden of high-cost veteran medications to the VA.
Rep. Doggett bought $1,001 - $15,000 in $JNJ on March 4, 2025, 93 days before the Treat and Reduce Obesity Act of 2025 (S.1973) was introduced, which aims to expand Medicare coverage for obesity treatments.
These flags identify timing coincidences between stock trades and legislative activity. They do not imply wrongdoing. Click any bill number or ticker to see the full analysis.
Share This Filing
All Transactions
| Type | Ticker | Asset | Amount | Trade Price | Current | Change | Date |
|---|---|---|---|---|---|---|---|
| BUY | $HD | Home Depot, Inc. (HD) | $1K-$15K | — | $335.89 | — | Mar 27, 2025 |
| BUY | $IBM | International Business Machines Corporation Common Stock (IBM) | $1K-$15K | — | — | — | Mar 10, 2025 |
| BUY | $JNJ | Johnson & Johnson Common Stock (JNJ) | $1K-$15K | — | — | — | Mar 4, 2025 |
| BUY | $PPG | PPG Industries, Inc. Common Stock (PPG) | $1K-$15K | — | — | — | Mar 12, 2025 |
Connected Legislative Activity
10 signalsThese bills and contracts share tickers or sectors with this filing's trades.
ABC Safe Drug Act
The ABC Safe Drug Act (S. 1407) is in early legislative stages, having been referred to the Senate Finance Committee. It phases in restrictions on federal health programs purchasing drugs with Chinese active ingredients by 2030 and provides temporary tax incentives for domestic pharmaceutical manufacturing. Major pharma stocks ($PFE, $MRK, $JNJ, $LLY, $AMGN) show mixed but broadly negative 7-day changes, reflecting sector headwinds rather than this nascent bill. No market-moving impact is imminent.
American Innovation and R&D Competitiveness Act of 2025
HR1990, the American Innovation and R&D Competitiveness Act, would restore immediate expensing for R&D costs, reversing the 2022 tax code change that required 5/15-year amortization. This is an early-stage bill referred to Ways and Means with 81 cosponsors, but if enacted, it would provide a direct 21% tax-rate cash flow benefit annually to every R&D-intensive US company. The largest absolute beneficiaries are mega-cap tech and pharma firms with $10B+ annual R&D budgets.
Ensuring Access to Essential Drugs Act
HR1922 is an early-stage bill referred to committee with no market impact. It would exempt certain orally administered brand-name drugs from Medicare Part D rebate obligations, but no hearings, votes, or further action have occurred since introduction on 2025-03-06.
Providing Veterans Essential Medications Act
HR1970 (Providing Veterans Essential Medications Act) is in early legislative stages, having been referred to the House Veterans' Affairs subcommittee. The bill mandates VA reimbursement for high-cost medications dispensed to veterans in State nursing homes, but authorizes no specific funding and remains months from passage. Real market data shows CVS up 16% in 30 days while CAH is down 10%, reflecting broader distribution-sector dynamics rather than this early-stage bill.
MOMS Act
The MOMS Act (S.1630) is an early-stage bill referred to committee with no authorized funding amount. It creates a procedural requirement for HHS to build a pregnancy.gov website. There is no near-term market impact. Recent declines in $ACN and $IBM are driven by broader tech weakness, not this legislation.
Modernizing Retrospective Regulatory Review
HR67 mandates federal agencies adopt AI-driven regulatory review tools, creating a new procurement category that benefits established FedRAMP-authorized cloud providers. The bill is pure authorization with no direct appropriations, but structural adoption requirements generate recurring revenue for $ORCL, $IBM, and $MSFT. Partner AI providers (e.g., Palantir, C3.ai) are secondary beneficiaries with lower confidence.
Climate Change Financial Risk Act of 2025
The Climate Change Financial Risk Act of 2025 (HR2823) would impose mandatory biennial climate risk capital evaluations and resolution plans on large U.S. banks. This creates direct compliance costs for JPMorgan, Bank of America, Citigroup, Goldman Sachs, and Morgan Stanley, while generating demand for consulting and IT services from Accenture and IBM. The bill is in early legislative stages with a companion bill in the Senate, but has low near-term passage probability given partisan dynamics and its early committee referral status.
Medicare for All Act
Medicare for All Act (HR3069) would eliminate private health insurance, replacing it with a single-payer federal program. The bill is in early legislative stages (referred to 7 committees, 114 cosponsors, all Democrats). Recent real market data shows private insurers rallied 20-70% over the past 30 days on unrelated factors (likely earnings or regulatory clarity), not legislative risk. A structural existential threat exists for managed care companies if this bill advanced to law — but current legislative probability near zero given Republican House control and early-stage procedural status.
Access to Pediatric Technologies Act of 2025
HR1931, the Access to Pediatric Technologies Act, is an early-stage House bill that would require CMS to establish Medicare payment methodologies for qualifying pediatric devices and drugs upon manufacturer request. The bill is referred to two committees with no further action in over a year. It authorizes no direct funding - it creates a regulatory pathway. For med-tech and pharma companies with pediatric product lines (JNJ, ABT, MRK, PFE), the bill is directionally positive but procedurally distant from becoming law.
Addressing Boarding and Crowding in the Emergency Department
HR2936 (ABC-ED Act) authorizes zero new funding and remains in early committee stage with no near-term market impact. The bill expands eligibility for existing public health data modernization grants to include hospital bed capacity tracking at the state and regional level, but any fiscal effect requires separate appropriations.
Other Filings by Lloyd Doggett
Data sourced from the U.S. House of Representatives Office of the Clerk Financial Disclosure system. Stock prices from Financial Modeling Prep. Suspicious timing flags identify coincidences between stock trades and legislative activity and do not imply any wrongdoing or illegal activity. This is not financial advice.